<DOC>
	<DOC>NCT00478231</DOC>
	<brief_summary>To collect safety and tolerability data in a more diverse patient population of patients with HIV/Aids, who have limited therapeutic options.</brief_summary>
	<brief_title>Multicenter, Safety Study Of Maraviroc</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Subjects with limited or no approved treatment options available to them due to resistance or intolerance; Subjects must be failing to achieve adequate virologic suppression on their current regimen and have HIV1 RNA â‰¥ 1000 copies/ml, at screening. Have only R5 HIV1 at Screening as verified by the Monogram Biosciences Trofile assay. Failed prior treatment with any CCR5 antagonist, in any ongoing CCR5 trials or having previously discontinued Maraviroc in trials Potentially life threatening (Grade 4) laboratory abnormality or medical condition (according to the Division of AIDS table for grading severity of adult adverse experiences) still under investigation unless a diagnosis has been established and felt not to affect risk/benefit assessment or eventual interpretation of safety results, based on discussion between the investigator and Pfizer.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Multicenter</keyword>
	<keyword>Open Label</keyword>
	<keyword>Non-Comparative Safety Study Of Maraviroc</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>